Supernus Pharmaceuticals traded at $31.26 this Thursday August 11th, decreasing $0.33 or 1.04 percent since the previous trading session. Looking back, over the last four weeks, Supernus Pharmaceuticals lost 7.46 percent. Over the last 12 months, its price rose by 25.59 percent. Looking ahead, we forecast Supernus Pharmaceuticals to be priced at 31.27 by the end of this quarter and at 28.74 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
31.26
Daily Change
-1.04%
Yearly
25.59%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 6,095.00 -4.00 -0.07% -33.66%
Abbott 110.49 0.22 0.20% -10.03%
Aurora Cannabis Inc 2.04 -0.07 -3.32% -76.90%
Aerie Pharmaceuticals 11.09 -0.55 -4.73% -24.15%
ANI Pharmaceuticals 35.39 0.42 1.20% 16.95%
Bristol-Myers Squibb 74.46 -0.40 -0.53% 11.22%
Cara Therapeutics 11.63 -0.93 -7.40% -12.75%
Corcept Therapeutics 27.97 0.23 0.83% 36.17%
Endo International 0.39 -0.04 -8.85% -90.48%
Horizon Pharma 67.10 -1.31 -1.91% -37.17%
Jazz Pharmaceuticals 154.25 -3.18 -2.02% 5.90%
Lannett 0.58 0.01 1.39% -87.38%
Eli Lilly 301.17 -3.44 -1.13% 14.31%
Marinus Pharmaceuticals 5.77 -0.16 -2.70% -54.21%
Pacira 56.26 -0.95 -1.66% -3.55%
Pfizer 48.29 -1.66 -3.32% 2.22%
Perrigo 41.65 -0.13 -0.31% 0.90%
Revance Therapeutics 21.44 -0.13 -0.60% -18.14%
Supernus Pharmaceuticals 31.26 -0.33 -1.04% 25.59%
Teva Pharmaceutical Industries 11.09 -0.11 -0.98% 11.01%
United Therapeutics 220.41 -1.08 -0.49% 8.55%
Canopy Growth Corp 4.01 -0.18 -4.30% -82.72%
Xeris Pharmaceuticals Inc 1.82 -0.11 -5.70% -25.10%

Indexes Price Day Year
USND 12780 -74.89 -0.58% -13.74%
US2000 1975 6.01 0.31% -11.98%

Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.